Semaglutide is properly tolerated with no hazard of hypoglycaemia in monotherapy but suffers from gastrointestinal adverse results. A large populace afflicted with COVID-19 an infection had been diabetic; therefore use of semaglutide in diabetes and CV sufferers can be very much supportive in keeping health care technique during this pandemic https://virgilh554tfp7.wikissl.com/user